Login to Your Account

ImmusanT $20M Series A To Advance Celiac Program

By Marie Powers
Staff Writer

Wednesday, December 14, 2011
ImmusanT Inc. is taking its Nexvax2 program for celiac disease to the next level, raising $20 million in a Series A from Vatera Healthcare Partners LLC to fund the immunotherapeutic vaccine and a companion diagnostic to proof of concept.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription